Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oligopinn is an oral dietary supplement developed by INNventa Pharm, specifically positioned for cardiovascular health. The product contains a standardized extract of French maritime pine bark (*Pinus pinaster*), which is rich in oligomeric proanthocyanidins (OPCs). Oligopinn is marketed to support microcirculation, maintain healthy blood pressure levels, and provide antioxidant protection. Its mechanism of action involves the stimulation of nitric oxide synthase, which increases the production of nitric oxide to facilitate vasodilation and improve endothelial function. Additionally, the extract exhibits anti-inflammatory properties by inhibiting pro-inflammatory mediators such as NF-kappaB and COX-2, and acts as a scavenger of reactive oxygen species to mitigate oxidative stress.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Oligopinn.